



ENDOSENSE BUILDS FURTHER VALIDATION FOR THE TACTICATH® WITH  
A HOST OF NEW CLINICAL ABSTRACTS

GENEVA – June 17, 2010 – [Endosense](#), a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced the unveiling of five new clinical abstracts on the use of contact force sensing in catheter ablation at Cardiostim 2010, June 16 – 19 in Nice, France. The abstracts, which feature the company’s [TactiCath](#) force-sensing ablation catheter, build on a [growing body of research](#) demonstrating the potential of contact force sensing to improve the safety and effectiveness of catheter ablation procedures.

The new research offers fresh insights into the role contact force plays in atrial fibrillation (AF) recurrence rates as well as the dynamic behavior of contact force during the cardiac cycle. Among the key findings, authors concluded that:

- There is a significant relationship between tip-to-tissue contact force and AF recurrences following catheter ablation for paroxysmal AF, with low contact forces associated with a higher rate of recurrence;
- Catheter orientation, applied force and the use of a long sheath significantly affect the dynamic range of contact force with implications for safety of catheter manipulation. A greater dynamic range may indicate more stable catheter placement and less potential for poor lesion creation; and
- The dynamic range of contact force is different at different sites in the left atrium. A controlled dynamic range may contribute to more stable catheter placement while ensuring good lesion creation.

“Our growing body of scientific data represents the deepest examination of contact force sensing ever conducted, and the findings continue to indicate its great potential to improve the way cardiac ablation procedures are performed,” said Eric Le Royer, chief executive officer of Endosense. “The implications for physicians and patients are tremendous, as the data suggests that force-sensing catheter ablation may in fact yield a better patient outcome.”

The TactiCath force-sensing ablation catheter and the TactiSys system are indicated for the treatment of atrial fibrillation (AF) and supraventricular tachycardia (SVT). BIOTRONIK is the exclusive distributor of the TactiCath in Europe, Latin America, Canada, Africa, and Middle East. The TactiCath is not yet available in the United States.

### **About the TactiCath**

Endosense's TactiCath is the first and only force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure. It has undergone considerable pre-clinical and clinical validation, the results of which have created a solid foundation of evidence supporting the feasibility, safety and value of contact-force sensing during catheter ablation. The TactiCath has the potential to improve the effectiveness, safety and reproducibility of catheter ablation treatment of cardiac rhythm disorders, including AF.

### **About Endosense**

Founded in Geneva in 2003, Endosense is a medical technology company focused on improving efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. The company has pioneered the use of contact force measurement in catheter ablation, with the development of its proprietary Touch+<sup>®</sup> sensor technology. Endosense's flagship product is the TactiCath, the first force-sensing ablation catheter to give physicians a real-time, objective measure of contact force during the catheter ablation procedure.

Endosense is backed by Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie. For more information, visit [www.endosense.com](http://www.endosense.com).

#### **MEDIA CONTACT/U.S.:**

Laura Nobles  
Nobles Communications  
310-795-0497  
[laura@noblescommunications.com](mailto:laura@noblescommunications.com)

#### **MEDIA CONTACT/EUROPE:**

Danièle Castle  
Genevensis Communications  
+41 22 779 06 20  
[info@genevensis.com](mailto:info@genevensis.com)

###